UK Markets close in 8 hrs 19 mins

Organon & Co. (OGN)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
35.86+0.94 (+2.69%)
At close: 04:04PM EDT
34.93 -0.93 (-2.59%)
After hours: 06:55PM EDT

Organon & Co.

30 Hudson Street
Floor 33
Jersey City, NJ 07302
United States
551 430 6000
https://www.organon.com

Sector(s)Healthcare
IndustryDrug Manufacturers—General
Full-time employees9,300

Key executives

NameTitlePayExercisedYear born
Mr. Kevin AliCEO & DirectorN/AN/A1960
Mr. Matthew M. WalshExec. VP & CFON/AN/A1967
Ms. Rachel A. StahlerExec. VP & Chief Information OfficerN/AN/A1976
Ms. Jennifer HalchakVP of Investor RelationsN/AN/AN/A
Ms. Deborah H. TelmanExec. VP, Gen. Counsel & Company Sec.N/AN/A1965
Mr. Aaron FalcioneExec. VP & Chief HR OfficerN/AN/A1971
Ms. Susanne Gabriele FiedlerExec. VP & Chief Commercial OfficerN/AN/A1968
Dr. Sandra Milligan J.D., M.D.Exec. VP and Head of R&DN/AN/A1964
Mr. Joseph T. Morrissey Jr.Exec. VP and Head of Manufacturing & SupplyN/AN/A1965
Mr. Vittorio NisitaExec. VP & Head of Global Bus. ServicesN/AN/A1968
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.

Corporate governance

Organon & Co.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.